Fusion Pharmaceuticals Inc. Long-Term Debt, Maturity, Year Two
Fusion Pharmaceuticals Inc. had Long-Term Debt, Maturity, Year Two of $10.65 million as of 2023-12-31, per its 10-K filed 2024-03-20.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2024-05-07
- 2023-12-31: Long-Term Debt, Maturity, Year Two $10.65M.
- 2023-09-30: Long-Term Debt, Maturity, Year Two $26.09M; Long-Term Debt, Maturity, Year Two as first filed $10.65M.
- 2023-06-30: Long-Term Debt, Maturity, Year Two $10.65M.
- 2023-03-31: Long-Term Debt, Maturity, Year Two $10.65M.
| Period end | Long-Term Debt, Maturity, Year Two | Long-Term Debt, Maturity, Year Two as first filed |
|---|---|---|
| 2023-12-31 | $10.65M 10-K · filed 2024-03-20 | |
| 2023-09-30 | $26.09M 10-Q · filed 2024-05-07 | $10.65M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $10.65M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $10.65M 10-Q · filed 2023-05-11 |